Think of the brain as a high-security fortress with a wall called the blood-brain barrier that keeps 98% of medicines out. This technology acts like a specialized key or a delivery shuttle that tricks the wall into letting the medicine through. Once inside, the drug can reach the brain cells to treat serious diseases that were previously unreachable.
Approximately 98% of potential brain-targeting drugs fail because they cannot cross the blood-brain barrier. This leaves millions of patients with CNS disorders and paediatric brain tumours without effective treatment options.
A platform of three patented peptide-shuttle families and a flagship product, G2B-002, designed for paediatric high-grade gliomas.
If you are a drug development firm dealing with candidates that cannot reach the central nervous system — this project developed peptide-shuttles that allow therapeutic molecules to cross the blood-brain barrier. This prevents the failure of candidates that otherwise make up 98% of drug attempts.
If you are a specialized oncology lab dealing with incurable paediatric brain tumours — this project developed G2B-002 to deliver treatment to high-grade gliomas. This addresses a pressing unmet medical need for tumours with an intact blood-brain barrier.
If you are a developer dealing with large molecules like antibodies that are too big to enter the brain — this project developed a platform to enhance the biopharmaceutical properties of these cargoes. This enables the transport of proteins and nanoparticles into the CNS.
Based on available project data, specific pricing for the shuttles or licensing costs are not disclosed.
The project has conducted evaluations on the active pharmaceutical ingredient (API) and raw materials and has secured a reliable supplier for key components of G2B-002.
The platform technology is based on three patented families of peptide shuttles.
The objective is to initiate clinical trials in paediatric brain tumours by 2026, following the completion of preclinical regulatory studies and the IMPD.
The peptide-shuttles are conjugated with cargoes such as small molecules, peptides, nanoparticles, proteins, and antibodies to enhance their transport.
The project is led by a single Spanish SME, GATE2BRAIN SL, with a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the company manages both the technology development and the regulatory path toward clinical trials without relying on academic partners.
Contact GATE2BRAIN SL in Spain regarding G2B-002 licensing
Contact us to identify potential partners for CNS drug delivery
